To characterise small photon beams using the Monte Carlo dose calculation algorithm for small field ranges in a heterogeneous medium.

An in-house phantom constructed with three different mediums, foam, polymethyl methacrylate and delrin resembling the densities of lung, soft tissue and bone respectively, was used in this study. Photon beam energies of 6 and 15 MV and field sizes of 8×8, 16×16, 24×24, 32×32 and 40×40 mm using X-ray voxel Monte Carlo (XVMC) algorithm using different detectors were validated. The relative output factor was measured in three different mediums having six different tissue interfaces; at the depth of 0, 1, 2 and 3 cm. The planar dose verification was undertaken using gafchromic films and considered dose at the lung and bone medium interfaces. For all the measurements, 104×104 mm was taken as the reference field size. The relative output factor for all other field sizes was taken and compared with planning system calculated values.

From field size 16×16 mm and above, the relative output factors were analysed in bone and soft tissue medium having lung as first medium. The maximum deviations were observed as 1·8 and 1·3% for 6 MV and 2·5 and 1·1% for 15 MV photon beams for bone and soft tissue, respectively. For lung as measurement medium, the maximum deviation of 14·8 and 19·2% were observed and having bone as first medium with 8×8 mm for 6 and 15 MV photon beams, respectively. The fluence verification of dose spectrum for the lung–bone interface scenarios with smaller field sizes were found within 2% of deviation with treatment planning system (TPS).

The accuracy of dose calculations for small field sizes in XVMC-based treatment planning algorithm was studied in different inhomogeneous mediums. It was found that the results correlated with measurement data for field size 16×16 mm and above. Noticeable deviation was observed for the smallest field size of 8×8 mm with interfaces of significant change in density. The observed results demands further analysis of work with smaller field sizes.

To evaluate the quality of rectal hydrogel spacer (HS) insertions from literature in patients undergoing radical radiotherapy for prostate cancer. The secondary aim is to assess the benefit of HSs in patients with risk factors more likely to have rectal complications, such as non-conventional radiotherapy dose fractionations and high-risk disease.

A literature search of peer-reviewed electronic articles was carried out using Boolean connectors and Medical Subject Headings in the databases. Databases searched included ScienceDirect, Medline and Cinahl. The articles were assessed using relevant critical appraisal skills programme tools.

From the 26 studies used, HS showed a clinically significant relative reduction in rectal planning dose volumes for both high- and low-risk prostate cancer patients in a range of radiotherapy treatment modalities including volumetric modulated arc therapy, intensity-modulated radiotherapy, intensity-modulated proton therapy, stereotactic ablative body radiotherapy and brachytherapy. Spacer placements were successfully inserted in 99% of patients. However, rectal wall infiltration occurrence was 6% and ≥2 cm unsymmetrical placements in 2%.

A spacer scoring system based on the HS symmetry has provided evidence of the quality of the position inserted, which was visually aided by T2-wieghted MRIs. Despite optimal HS placements ranging from 62 to 72%, HS had a clinically significant reduction of ≥25% in planned rectal V70 dose in 97% of patients.

Superficial X-ray therapy units are used for the treatment of certain types of skin cancer and some severe dermatological conditions. The performance assessment and beam characteristics of the superficial unit are very important to ensure accurate dose delivery during patient treatment. Both experimental measurements and Monte Carlo calculations can be used for this purpose.

This study aims to investigate whether it is possible to reproduce experimentally measured data for the XSTRAHL 150 superficial X-ray unit with simulations using the BEAMnrc Monte Carlo code.

The experimental procedure applied in this study included the following: experimental measurements of different X-ray spectra, half-value layers, percentage depth dose and beam profiles. Monte Carlo modelling of the XSTRAHL 150 unit was performed with the BEAMnrc code. The validity of the model was checked by comparing the theoretical calculations with experimental measurements.

There was good agreement (∼1%) between experimentally measured and simulated X-ray spectra. Results of half-value layers obtained from simulated and measured spectra showed that there was a maximum of 3·6% difference between BEAMnrc and measurements and a minimum of 2·3%. In addition, simulated percentage depth dose and profile curves have been compared against experimental measurements and show good agreement (within 2% for the depth dose curves and 3–5% for beam profile curves, depending on the applicator size).

The results of this study provide information about particles’ interaction in different kilovoltage and filter combinations. This information is useful for X-ray tube design and development of new target/filter combinations to improve beam quality in superficial X-ray radiotherapy. The data presented here may provide a base for comparison and a reference for other or potential new users of the XSTRAHL 150 X-ray unit.

To investigate the necessity of rotational shifts by considering dosimetric impact of rotational errors on stereotactic body radiation therapy (SBRT).

20 lung patients with the lesion size <5 cm treated with SBRT have been selected for dosimetric analysis. Three-dimensional dose has been rotationally shifted (±1°, ±3°, ±5° for pitch, roll and yaw) and overlaid to the original computed tomography images. The dose–volume histograms of 18-rotational plans of each patient were compared to those of the original plan.

No significant dosimetric differences were observed in target coverage. For all of the cases up to 5° in any couch angle dose differences of D99 and D95 were <3%. Variations of conformity index were observed to be less than 0·05. None of the organ at risk doses exceeded the dose limit. The V20 differences of the ipsilateral and the total lungs were less than 0·4%.

It has been found to be unnecessary to perform rotational shifts up to 5° for lung SBRT treatments; the translational shift is sufficient for the cases used in this study. This method may be applied and tested after planning and before treatment initiation to rule out exceptionally extreme cases.

The novel three-dimensional (3D) radiotherapy interactive outlining tool allows volumes to be created from a handful of points within axial, sagittal and coronal planes. 3D volumetric visualisation allows users to directly manipulate the resulting volume using innovative-sculpting tools. This paper discusses the development and initial evaluation of the software ahead of formal clinical testing.

User feedback was collated as part of the software development phase to ensure clinical suitability, define user training strategies and identify best practice. A loosely structured format was adopted with leading descriptive questions aiming to generate suggestions for improvements and initiate further discussion.

The four participants reported great satisfaction and value in being able to use all three planes for outlining, although orientation in 3D was evidently a problem. All participants felt that the software was capable of producing acceptable outlines rapidly and that the multi-planar capability allowed for improved outlining of the prostate apex.

Mesh generation from a small number of points placed on a range of planes is a rapid and effective means of target delineation. Multi-slice volume sculpting and 3D orientation is challenging and may indicate a need for a paradigm shift in anatomy and computed tomography training.

This study aimed to systematically review the literature to synthesise and summarise whether using knowledge-based planning (KBP) can improve the planning of stereotactic radiotherapy treatments.

A systematic literature search was carried out using Medline, Scopus and Cochrane databases to evaluate the use of KBP planning in stereotactic radiotherapy. Three hundred twenty-five potential studies were identified and screened to find 25 relevant studies.

Twenty-five studies met the inclusion criteria. Where a commercial KBP was used, 72.7% of studies reported a quality improvement, and 45.5% reported a reduction in planning time. There is evidence that when used as a quality control tool, KBP can highlight stereotactic plans that need revision. In studies that use KBP as the starting point for radiotherapy planning optimisation, the radiotherapy plans generated are typically equal to or superior to those planned manually.

There is evidence that KBP has the potential to improve the quality and speed of stereotactic radiotherapy planning. Further research is required to accurately quantify such systems’ quality improvements and time savings. Notably, there has been little research into their use for prostate, spinal or liver stereotactic radiotherapy, and research in these areas would be desirable. It is recommended that future studies use the ICRU 91 level 2 reporting format and that blinded physician review could add a qualitative assessment of KBP system performance.

Radiotherapy clinical trials are at the forefront of modern-day prostate cancer patient management. Patients are reviewed during treatment by clinical oncologists or competent on-treatment review radiographers to minimise treatment toxicities. Clinical Research Radiographers (CRRs) routinely monitor and gather research data from patients participating in clinical trials.

The aim of this article is to evaluate the effectiveness of the CRR undertaking the on-treatment review of clinical trial patients.

An experienced CRR within the Northern Ireland Cancer Trials Network was supervised by a clinical oncologist to undertake the role of the on-treatment review of patients receiving radiotherapy for prostate cancer. The CRR explored published literature and compiled this written evaluation as part of their advanced practice learning.

The supervising clinical oncologist verified, following the planned period of supervised practice and academic study, that the CRR was competent to fulfil the role. Evidence of the beneficial synergistic impact of co-joining the roles was experienced at first hand during the undertaking of supervised practice.

Co-joining the roles and responsibilities of the CRR and the on-treatment review radiographer enhanced the quality of care offered to the patients participating in clinical trials.

Lung cancer has a high mortality rate mainly due to the lack of early detection or outward signs and symptoms, thereby often progressing to advanced stages (e.g., stage IV) before it is diagnosed. However, if lung cancers can be diagnosed at an early stage and also if clinicians can prospectively identify patients likely to respond to specific treatments, then there is a very high potential to increase patients’ survival. In recent years, several investigations have been conducted to identify cancer biomarkers for lung cancer risk assessment, early detection and diagnosis, the likelihood of identifying the group of patients who will benefit from a particular treatment and monitoring patient response to treatment.

This paper reports on the review of 19 current clinical and emerging biomarkers used in risk assessment, screening for early detection and diagnosis and monitoring the response of treatment of non-small-cell lung cancers.

The future holds promise for personalised and targeted medicine from prevention, diagnosis to treatment, which take into account individual patient’s variability, though it depends on the development of effective biomarkers interrogating the key aberrant pathways and potentially targetable with molecular targeted or immunologic therapies. Lung cancer biomarkers have the potential to guide clinical decision-making since they can potentially detect the disease early, measure the risk of developing the disease and the risk of progression, provide accurate information of patient response to a specific treatment and are capable of informing clinicians about the likely outcome of a cancer diagnosis independent of the treatment received. Moreover, lung cancer biomarkers are increasingly linked to specific molecular pathway deregulations and/or cancer pathogenesis and can be used to justify the application of certain therapeutic or interventional strategies.

Weekly low-dose cisplatin is routinely used in concurrent chemoradiation (CCRT) in locally advanced head and neck cancer (LAHNC), despite 3-weekly cisplatin being the standard of care. We compared compliance, toxicity and efficacy in weekly versus 3-weekly cisplatin CCRT in LAHNC.

In this retrospective study, weekly cisplatin 50 mg flat dose was compared with 3-weekly cisplatin 100 mg/m2, when given in CCRT in LAHNC with curative intent. The study outcome was compliance, toxicity, loco-regional control (LRC), disease-free survival (DFS) and overall survival (OS).

Eighty-four patients received CCRT from January 2013 to June 2017, 40 in weekly and 44 in 3-weekly arm. There was no difference between the arms not completing scheduled radiation therapy or chemotherapy. Patient receiving 200 mg/m2 cisplatin is higher in 3-weekly arm compared with weekly arm (75 versus 40·9%; p<0·0015). Compared with 3-weekly arm, more patient in weekly arm developed grade ≥3 mucositis (52·5 versus 15·9%, p=0·0004), day care intravenous hydration (82·5 versus 38·6% <0·0001) and in-patient admission (55·0 versus 18·2%; p=0·0004). The 2-year LRC, DFS and OS in weekly versus 3-weekly arm were: 70 versus 61·4% (p=0·406); 67·5 versus 56·8% (p=0·314); 67·5 versus 61·4% (p=0·558), respectively. The median time to LRR, DFs and OS was not reached.

Weekly cisplatin is comparable with 3-weekly cisplatin in terms of compliance, disease control and survival, but with increased grade 3 mucositis and higher admissions for supportive care.

The purpose of this study is to introduce a new approach to assess the dosimetry quality of photon beam with energy and irradiation field size. This approach is based on percentage depth dose (PDD) fragmentation for investigating the dosimetry quality.

For the investigation of the dosimetry quality of 6 and 18 MV photon beams, we have proceeded to fragment the PDD at different field sizes. This approach checks the overall PDD and is not restricted to the exponential decay regions, as per the International Atomic Energy Agency Technical Reports Series No 398 and the American Association of Physicist in Medicine Task Group 51 recommendations.

The 6 MV photon beam deposited more energy in the target volume than the 18 MV photon beam. The dose delivered by the 6 MV beam is greater by a factor of 1·5 than that delivered by the 18 MV beam in the build-up region and the dose delivered by the 6 MV beam is greater by a factor of 2·6 than that delivered by the 18 MV beam in the electronic equilibrium and the exponential decay regions.

The dose measured at different points of the beam is higher for 6 MV than for 18 MV photon beam. Therefore, the 6 MV beam is more dosimetrically efficient than the 18 MV beam. Using the proposed approach, we can assess the dosimetry quality by taking into account overall PDD not only in the exponential decay region but also in the field.

This National Cancer Database (NCDB) analysis was performed to evaluate the outcomes of adjuvant chemotherapy (AC) versus observation for resected pancreatic adenocarcinoma treated with neoadjuvant therapy (NT).

The NCDB was queried for primary stages I–II cT1-3N0-1M0 resected pancreatic adenocarcinoma treated with NT (2004–2015). Baseline patient, tumour and treatment characteristics were extracted. The primary end point was overall survival (OS). With a 6-month conditional landmark, Kaplan–Meier analysis, multivariable Cox proportional hazards method and 1:1 propensity score matching was used to analyse the data.

A total of 1,737 eligible patients were identified, of which 1,247 underwent post-operative observation compared to 490 with AC. The overall median follow-up was 34·7 months. The addition of AC showed improved survival on the multivariate analysis (HR 0·78, p < 0·001). AC remained statistically significant for improved OS, with a median OS of 26·3 months versus 22·3 months and 2-year OS of 63·9% versus 52·9% for the observation cohort (p < 0·001). Treatment interaction analysis showed OS benefit of AC for patients with smaller tumours.

Our findings suggest a survival benefit for AC compared to observation following NT and surgery for resectable pancreatic adenocarcinoma, especially in patients with smaller tumours.

Nasopharyngeal carcinoma (NPC) patients may have anatomical variations during their radiotherapy treatment course. In this study, we determine the daily accumulated dose by the deformable image registration (DIR) process for comparing with the planned dose and explore the number of fractions which the daily accumulated dose significantly changed from the planned dose.

The validation of the DIR process in MIM software has been tested. One hundred and sixty-five daily megavoltage computed tomography (MVCT) images of NPC patients who were treated by helical tomotherapy were exported to MIM software to determine the daily accumulated dose and then compared with the planned dose.

The MIM software illustrated the acceptable validation for clinical application. The accumulated dose (D50%) of the planning target volume (PTV70) showed a decrease from the planned dose with an average of 0.5 ± 0.27% at the end of the treatment and was significantly different from the planned dose after the second fraction of the treatment (p-value = 0.008). In contrast, the accumulated dose of organ at risk (OAR) tended to increase from the planned dose and was significantly different after the fifth fraction (left parotid), the twelfth fraction (right parotid) and the second fraction (spinal cord).

The inter-fractional anatomic changes cause the actual dose to be different from the planned dose. The dose differences and the number of fractions were varied in each target and OAR. The dose accumulation explored the necessary information for the radiation oncologist to consider adaptive treatment strategies to increase the efficiency of treatment.